RESUMO
The entero-mammary pathway is a specialized route that selectively translocates bacteria to the newborn's gut, playing a crucial role in neonatal development. Previous studies report shared bacterial and archaeal taxa between human milk and neonatal intestine. However, the functional implications for neonatal development are not fully understood due to limited evidence. This study aimed to identify and characterize the microbiota and metabolome of human milk, mother, and infant stool samples using high-throughput DNA sequencing and FT-ICR MS methodology at delivery and 4 months post-partum. Twenty-one mothers and twenty-five infants were included in this study. Our results on bacterial composition suggest vertical transmission of bacteria through breastfeeding, with major changes occurring during the first 4 months of life. Metabolite chemical characterization sheds light on the growing complexity of the metabolites. Further data integration and network analysis disclosed the interactions between different bacteria and metabolites in the biological system as well as possible unknown pathways. Our findings suggest a shared bacteriome in breastfed mother-neonate pairs, influenced by maternal lifestyle and delivery conditions, serving as probiotic agents in infants for their healthy development. Also, the presence of food biomarkers in infants suggests their origin from breast milk, implying selective vertical transmission of these features.
Assuntos
Aleitamento Materno , Fezes , Microbioma Gastrointestinal , Leite Humano , Humanos , Leite Humano/microbiologia , Leite Humano/química , Feminino , Recém-Nascido , Microbioma Gastrointestinal/fisiologia , Fezes/microbiologia , Lactente , Adulto , Metaboloma , Bactérias/metabolismo , Bactérias/classificação , Bactérias/genética , Masculino , MãesRESUMO
BACKGROUND: Congenital heart disease (CHD) are the most common malformations from birth. The severity of the different forms of CHD varies extensively from superficial mild lesions with follow-up for decades without any treatment to complex cyanotic malformations requiring urgent surgical intervention. microRNAs have been found to be crucial in cardiac development, giving rise to possible phenotypes in CHD. OBJECTIVES: We aimed to evaluate the expression of miRNAs in 86 children with CHD and divided into cyanotic and non-cyanotic heart defects and 110 controls. METHODS: The miRNAs expression of miR-21-5p, miR-155-5p, miR-221-3p, miR-26a-5p, and miR-144-3p were analyzed by RT-qPCR. In addition, the expressions of the miRNAs studied were correlated with the clinical characteristics of both the children and the mothers. RESULTS: The expression levels of miR-21-5-5p, miR-15-5p5, miR-221-3p, and miR-26-5p significantly differed between CHD and control subjects. Moreover, miR-21-5p levels were higher in patients with cyanotic versus non-cyanotic CHD patients. CONCLUSION: The expression levels of miRNAs of pediatric patients with CHD could participating in the development of cardiac malformations. Additionally, the high expression of miR-21-5p in cyanotic CHD children may be related to greater severity of illness relative to non-cyanotic CHD. IMPACT: This study adds to knowledge of the association between microRNAs and congenital heart disease in children. The expression levels of miR-21-5-5p, miR-15-5p5, miR-221-3p, and miR-26-5p of pediatric patients with CHD could be involved in the development and phenotype present in pediatric patients. miR-21-5p may help to discriminate between cyanotic and non-cyanotic CHD. In the future, the miRNAs studied could have applications as clinical biomarkers.
RESUMO
Introduction: The mother's colostrum carries immunological components, such as cytokines and immunoglobulins (Igs), derived from the maternal circulation with bacteriostatic properties. Objective: The objective of this study was to evaluate the effect of oropharyngeal administration of colostrum (OPAC) vs. placebo in the first 4 days of life in premature newborns ≤32 weeks of gestation on serum Ig concentration, neonatal morbidity, and total days of hospitalization. Hypothesis: The OPAC increases serum Igs and decreases morbidity and total days of hospitalization. Materials and Methods: A double-blind randomized controlled trial was carried out. Participants were randomly assigned to one of the two groups, namely, group 1: placebo (P) (n = 50) and group 2: colostrum (C) (n = 46). A blood sample was obtained at baseline and 7 and 28 days of life to quantify immunoglobulin G (IgG), immunoglobulin A (IgA), and IgM. Results: The C group showed an increase in serum IgA on day 28 expressed as median and [interquartile range]; C: 25 [12-35] vs. P: 11 [8-18], p < 0.001. There were no significant differences in neonatal morbidity. Newborns in the colostrum group showed the completed enteral feeding earlier (days), C: 13.9 ± 7 vs. P: 17.4 ± 8.4, p < 0.04; they reached the birth weight earlier, C: 10.9 ± 2.8 vs. P: 12.9 ± 4, p < 0.01, and had less days of hospitalization, C: 60.2 ± 33.8 vs. P: 77.2 ± 47.3, p < 0.04. Neonatal mortality was lower in the colostrum group than the placebo group 0% vs. 12%, respectively, without a statistical difference (p = 0.06). Conclusion: In premature newborns ≤32 weeks of gestation, the OPAC within 4 days after birth increases serum IgA concentration at day 28 compared to placebo. Similarly, OPAC decreased the days to complete enteral feeding and reach the birth weight and total days of hospitalization. Clinical Trial Registration: [https://clinicaltrials.gov/ct2/show/NCT03578341], identifier: [NCT03578341].
Assuntos
Antioxidantes/uso terapêutico , Suplementos Nutricionais , Recém-Nascido de muito Baixo Peso , Retinopatia da Prematuridade/prevenção & controle , Vitamina E/uso terapêutico , Administração Oral , Antioxidantes/administração & dosagem , Método Duplo-Cego , Esquema de Medicação , Feminino , Humanos , Recém-Nascido , Masculino , Estresse Oxidativo , Soluções , Vitamina E/administração & dosagemRESUMO
Introducción: La corioamnionitis es común durante el embarazo y se asocia con diversas complicaciones perinatales; entre los problemas neonatales más frecuentes están: parto pretérmino, sepsis neonatal, enfermedad pulmonar crónica, lesión cerebral secundaria a infección y trastornos del desarrollo neurológico. Es necesario conocer el riesgo de sepsis neonatal temprana en recién nacidos hijos de madres con corioamnionitis, con la intención de plantear estrategias para su prevención y tratamiento. Objetivos: Determinar el grado de asociación entre la corioamnionitis materna y la aparición de sepsis neonatal temprana. Métodos: Se realizó un estudio de casos y controles donde se incluyeron 148 pacientes divididos en dos grupos: grupo I, los casos, hijos de madres con corioamnionitis (n = 74), y grupo II, control, neonatos sin antecedente de corioamnionitis materna (n = 74). Resultados: El grupo de madres con corioamnionitis tuvo menor control prenatal y sus recién nacidos, a pesar de haber recibido antibiótico profiláctico, tuvieron una mayor frecuencia de sepsis y problemas respiratorios. Conclusiones: Los hijos de madres con corioamnionitis tienen un incremento en el riesgo de presentar sepsis neonatal temprana.
Introduction: Chorioamnionitis is common during pregnancy and associated with several perinatal complications, including postpartum infection and sepsis. Among the most frequent neonatal complications associated to chorioamnionitis are: preterm delivery, neonatal sepsis, chronic lung disease, brain injury secondary to infection, and other neurodevelopmental disorders. It is necessary to know what the risk is of early-onset neonatal sepsis in newborns to mothers with chorioamnionitis. Objective: Determine whether maternal chorioamnionitis has an association with early-onset neonatal sepsis. Methods: We performed a case-control study, in which we included 148 patients divided in two groups: group I, cases (n = 74) and group II, controls (n = 74). The sample size was calculated through difference of proportions. Results: The group of mothers with chorioamnionitis had less prenatal care, and their newborns had a larger number of infections and respiratory problems despite the indication of prophylactic antibiotic schemes. Conclusions: Newborn infants to mother with chorioamnionitis have an increased risk of early neonatal sepsis, despite the use of prophylactic antibiotics.
RESUMO
Introducción: En los últimos años ha habido un incremento de recién nacidos cercanos a término; esta prematurez tardía se asocia con un aumento en la morbilidad y mortalidad neonatal, por lo que es interesante conocer las diferencias en la morbilidad de este grupo de pacientes, en comparación con los recién nacidos a término. Objetivo: Evaluar la morbimortalidad temprana y durante el primer mes de vida del prematuro tardío en comparación con el recién nacido a término. Material y métodos: Se realizó un estudio comparativo de dos cohortes de recién nacidos. Grupo 1: recién nacidos prematuros tardíos de 34 a 36.6 semanas de gestación, y Grupo 2: recién nacidos a término. Se compararon 15 variables relacionadas a morbimortalidad. Se utilizó estadística descriptiva, para la comparación entre grupos t de Student y para comparar la morbilidad se determinó el riesgo relativo con el 95% de intervalo de confianza. Resultados: Se incluyeron 59 prematuros tardíos y 69 nacidos a término. De los factores maternos estudiados no hubo diferencias significativas. Respecto a los neonatos, existió un mayor riesgo del prematuro tardío para hiperbilirrubinemia (OR: 1.7 con IC 95% 1.1-2.65, reflujo gastroesofágico 1.8 con IC 95% 1.1-2.9 y dificultad en la alimentación (OR 1.66 con IC 95% 1.14-2.4). Conclusiones: Los riesgos de morbilidad encontrados en el prematuro tardío son aquellos que se presentan por su propia prematurez. No se encontró morbilidad en el prematuro tardío, secundaria a patología materna asociada.
Introduction: In recent years there has been an increase in the number of births of infants near term; this late prematurity is associated with increased neonatal morbidity and mortality, so it is important to know the differences in morbidity in this group of patients compared with term newborns, during the first month of life. Objective: To evaluate the early morbidity and during the first month of life of late preterm compared with term infants. Material and methods: We performed a comparative study of two cohorts of infants. Cohort 1: Late preterm infants from 34 to 36.6 weeks of gestation and Cohort 2; term infants. The morbidity was recorded during the first month of life, 15 variables were measure. We used descriptive statistic, for comparison between groups Student's t and to compare morbidity between groups the relative risk with 95% confidence interval. Results: We included 59 late preterm and 69 term infants. Of the maternal factors studied no statistically significant difference was found; respect to neonatal morbidity, we identified a great risk in the late preterm risk for hyperbilirubinemia (OR 1.7, CI 95% 1.1-2.65), gastroesophageal reflux (OR 1.8, CI 95% 1.1-289) and feeding difficulties (OR: 1.66, CI 95% 1.14-2.42). Conclusions: The risk of morbidity in late preterm found are those related to their own prematurity. In this study, there was no pathology associated with maternal morbidity in late preterm.
RESUMO
Introducción. La mortalidad neonatal es un indicador sensible y específico que nos permite conocer el estado de salud de un país y plantear estrategias para mejorarlo. Resulta de una cadena compleja de determinantes como los biológicos, los socioeconómicos y los de salud. El objetivo de este trabajo fue conocer la tasa de mortalidad neonatal general, por peso y edad gestacional, en un instituto de tercer nivel de atención durante 2007 y 2008. Métodos. Se analizaron todos los casos provenientes del comité de mortalidad perinatal y neonatal, de 2007 y 2008, desde 22 semanas de gestación en adelante. El análisis estadístico se realizó mediante medidas de tendencia central y dispersión para las variables cuantitativas y para las variables cualitativas frecuencia, porcentaje, χ² y razón de momios con nivel de significación estadística < 0.05. Resultados. La tasa de mortalidad para el año 2007 fue de 17.7 × 1000 nacidos vivos y para el 2008 de 19.7 × 1000 nacidos vivos. En relación con el peso y con la edad gestacional no se encontró aumento de riesgo al comparar los resultados de ambos años. Las malformaciones ocuparon el mayor porcentaje entre las causas de defunción. Conclusiones. Las tasas de mortalidad en 2007 y 2008 fueron de 17.7 y 19.7 × 1000 nacidos vivos, respectivamente. Las principales causas de defunción fueron las malformaciones cardiacas.
Background. Mortality is a sensitive and specific indicator for determining the health status of a country in order to implement improvement strategies. It is the result of biological, social, economic and health factors. The aim of this study was to determine neonatal general mortality and its relationship with weight and gestational age at a third-level health institution from 2007 to 2008. Methods. We analyzed all patients >22 weeks of gestational age from the perinatal mortality service. Statistical analysis was done using measures of central tendency and dispersion for quantitative variables and χ2, percentage and frequency for qualitative variables; odds ratios were calculated with significance level <0.05. Results. The mortality rate for 2007 was 17.7 per 1000 live births, and for 2008 it was 19.7 per 1000 live births. When we compared both years, we did not find an increased risk for weight and gestational age. Malformations occupied the largest causes of death. Conclusions. For years 2007 and 2008, mortality rates were 17.7 and 19.7 per 1000 live births, respectively, and the main cause of deaths were cardiac malformations.
RESUMO
Introducción. La prevalencia de colestasis neonatal varía del 7-57%. Parte del manejo incluye al ácido ursodesoxicólico (UDCA) y al fenobarbital, ambos con débil sustento en la literatura. El objetivo de este trabajo es comparar la efectividad del UDCA vs fenobarbital en la reducción de las cifras de bilirrubina directa, en recién nacidos prematuros con colestasis, con peso entre 1 000-2 000 g. Métodos. Se realizó un ensayo clínico aleatorizado cruzado en 18 pacientes. Cada individuo recibió al azar una de las dos intervenciones: UDCA (10 mg/kg/día c/12 h) o fenobarbital (a 3 mg/kg/día c/24 h) durante un período inicial de 7 días. Después de 7 días de lavado, se les asignó el tratamiento contrario. En total se realizaron 36 tratamientos. Se midieron bilirrubinas y pruebas de función hepática al inicio y final de cada tratamiento. El análisis se realizó por medio de medidas de tendencia central y de dispersión, de acuerdo al tipo de variable. Para la comprobación de hipótesis se realizó t pareada. Resultados. En el grupo que recibió UDCA a 10 mg/kg/día c/12 h por 7 días, disminuyeron las cifras de bilirrubina directa en 2.7 mg/dL (P<0.01). Conclusiones. Se recomienda el uso de UDCA a dosis de 10 mg/kg/día c/12 h por vía enteral como coadyuvante para el tratamiento de colestasis neonatal.
Background. The prevalence of neonatal cholestasis varies from 7-57%. Part of the treatment includes ursodeoxycholic acid (UDCA) and phenobarbital, both with little supporting evidence in the literature. We undertook this study to compare the effectiveness of phenobarbital vs. UDCA in reducing the direct serum bilirubin levels in patients with cholestasis and weighing from 1 000 to 2 000 g. Methods. Using a cross-randomized clinical trial, 18 patients were included with 36 treatments. Each subject randomly received one of the two interventions: UDCA (10 mg/kg/day) every 12 h or phenobarbital (3 mg/kg/day, every 24 h for 7 days) continuing with 7 days of wash-out to return to their initial state, and to subsequently receive the other treatment. At the beginning and at the end of the administration of each medication, bilirubin concentrations and hepatic test functions were measured. Central tendency and dispersion measurements were applied according to the type of variable. For hypothesis confirmation, paired t-test was carried out. Results. The obtained results indicate that with UDCA at a dose of 10 mg/kg/day every 12 h for 7 days, serum bilirubin levels decreased to 2.7 mg/dL (p <0.01). Phenobarbital had no effect in reducing bilirubin concentration. Conclusion. Use of UDCA is recommended at a dose of 10 mg/kg/dose every 12 h (PO) as a coadjuvant in the treatment of neonatal cholestasis.
RESUMO
INTRODUCTION: During the last decades the number of births in women with 35 or more years of age has increased approximately 35-50%. OBJECTIVE: To establish the neonatal morbidity associated with advanced maternal age, compared with mothers in the optimal reproductive stage. MATERIALS AND METHODS: This is a retrospective case-control survey. In 1999 we revised 210 records from neonates and mothers with 35 or more years of age (cases) and 210 records of neonates and mothers with age between 18 and 34 years (controls). The variability significance was established with t-student, X2 and risk with the probabilistic risk ratio. RESULTS: There was a significant difference in the socioeconomic and educational level. Advanced maternal age predisposed 2.43 times indication for cesarean section, increased the risk for gestational diabetes (11.35), toxemia (4.11) and in its severe form (2 times). Miscarriage menace (5.65 times). Lower birth weight (p < 0.007) and wet lung syndrome were more frequent in the advanced age group (p < 0.02). Risk for hypoglycemia was 1.62. There was also an increase in the risk for Trisomy 21 (p < 0.05) with an OR of 4 in cases. Genetic service evaluated 35 patients in the maternal advanced age group with an OR of 35. CONCLUSIONS: Advance maternal age increases maternal morbidity and the risk for preterm delivery, low birth weight, asymptomatic hypoglycemia, wet lung syndrome and risk for chromosomopathies.
Assuntos
Doenças do Recém-Nascido/epidemiologia , Idade Materna , Resultado da Gravidez/epidemiologia , Gravidez de Alto Risco , Adolescente , Adulto , Estudos de Casos e Controles , Cesárea/estatística & dados numéricos , Transtornos Cromossômicos/epidemiologia , Diabetes Gestacional/epidemiologia , Feminino , Humanos , Hipoglicemia/epidemiologia , Recém-Nascido de Baixo Peso , Recém-Nascido , Recém-Nascido Prematuro , Masculino , México/epidemiologia , Trabalho de Parto Prematuro/epidemiologia , Razão de Chances , Gravidez , Síndrome do Desconforto Respiratório do Recém-Nascido/epidemiologia , Estudos Retrospectivos , Risco , Fatores SocioeconômicosRESUMO
INTRODUCTION: During the last decades the number of births in women with 35 or more years of age has increased approximately 35-50. OBJECTIVE: To establish the neonatal morbidity associated with advanced maternal age, compared with mothers in the optimal reproductive stage. MATERIALS AND METHODS: This is a retrospective case-control survey. In 1999 we revised 210 records from neonates and mothers with 35 or more years of age (cases) and 210 records of neonates and mothers with age between 18 and 34 years (controls). The variability significance was established with t-student, X2 and risk with the probabilistic risk ratio. RESULTS: There was a significant difference in the socioeconomic and educational level. Advanced maternal age predisposed 2.43 times indication for cesarean section, increased the risk for gestational diabetes (11.35), toxemia (4.11) and in its severe form (2 times). Miscarriage menace (5.65 times). Lower birth weight (p < 0.007) and wet lung syndrome were more frequent in the advanced age group (p < 0.02). Risk for hypoglycemia was 1.62. There was also an increase in the risk for Trisomy 21 (p < 0.05) with an OR of 4 in cases. Genetic service evaluated 35 patients in the maternal advanced age group with an OR of 35. CONCLUSIONS: Advance maternal age increases maternal morbidity and the risk for preterm delivery, low birth weight, asymptomatic hypoglycemia, wet lung syndrome and risk for chromosomopathies.
Assuntos
Humanos , Masculino , Feminino , Gravidez , Recém-Nascido , Adolescente , Adulto , Doenças do Recém-Nascido/epidemiologia , Idade Materna , Resultado da Gravidez , Estudos de Casos e Controles , Cesárea/estatística & dados numéricos , Diabetes Gestacional , Hipoglicemia , Recém-Nascido de Baixo Peso , Recém-Nascido Prematuro , México , Trabalho de Parto Prematuro , Razão de Chances , Síndrome do Desconforto Respiratório do Recém-Nascido , Estudos Retrospectivos , Risco , Fatores Socioeconômicos , Transtornos Cromossômicos/epidemiologiaRESUMO
Introducción: Las enfermedades autoinmunes se presentan más frecuentemente en mujeres en edad de procreación, el prototipo de ellas es el lupus eritematoso sistémico (LES), que es una enfermedad multisistémica, crónica e inflamatoria. Objetivo: Evaluar el comportamiento de la morbimortalidad perinatal en un grupo de pacientes gestantes, identificando las complicaciones maternas y neonatales secundarias a LES.Material y métodos: En un estudio retrospectivo de seis años (1992-1997) se integraron 72 expedientes del binomio madre-hijo en donde se definieron como variables de estudio a las complicaciones materno neonatales secundarias a LES. Resultados: En la población materna con diagnóstico de LES se encontró en edad ideal reproductiva 84.7 por ciento, y en edades extremas 15.3 por ciento. El control prenatal efectivo se realizó en 87.5 por ciento y 16.6 por ciento ameritó por lo menos un internamiento durante la gestación. Las complicaciones más frecuentes fueron infecciosas (37.5 por ciento), hematológicas (13.9 por ciento) y renales (5.5 por ciento). No hubo mortalidad materna. En la población neonatal se determinó eutrofia en 58.3 por ciento e hipertrofia en 41.6 por ciento y en el mismo porcentaje se presentó prematurez (41.6 por ciento). Las complicaciones más frecuentes fueron hematológicas (18.0 por ciento), respiratorias (12.5 por ciento), metabólicas (8.3 por ciento) y bloqueo cardiaco y lesiones cutáneas (1.4 por ciento). Se diagnosticó lupus neonatal en 8.3 por ciento, la sobrevida en este grupo de recién nacidos fue de 94.4 por ciento. Comentario: La presencia de morbilidad materno-neonatal secundaria a LES se presentó en el binomio madre-hijo en un porcentaje <50 por ciento. Se determinaron las complicaciones infecciosas como las más frecuentes en las madres probablemente secundarias al tratamiento médico. De la población con lupus neonatal únicamente 2.8 por ciento presentó bloqueo cardiaco y lesiones cutáneas. El comportamiento materno y la repercusión neonatal no difieren en relación a otros autores. Sin embargo, es necesario investigar el comportamiento inmunológico y la predisposición genética, ya que existen diferencias en la distribución de antígenos de histocompatibilidad en cada población de estudio.
Assuntos
Humanos , Feminino , Gravidez , Adolescente , Adulto , Instalações de Saúde , Lúpus Eritematoso Sistêmico/epidemiologia , Morbidade , Mortalidade Perinatal , Assistência Perinatal/tendências , Complicações na GravidezRESUMO
El análisis de la morbimortalidad neonatal, en forma periódica, es uno de los mejores indicadores para evaluar la calidad asistencial, no solo en una unidad de cuidados intensivos neonatales, sino a nivel institucional. En un período de un año de estudió en forma prospectiva a todos los recién nacidos de muy bajo peso, es decir, neonatos con peso ó a 1,500 g, que ameritaron ventilación mecánica. Se dividieron en cuatro grupos de acuerdo al peso al nacimiento; grupo I con peso de 501 a 750 g; grupo II, 751 a 1000 g; grupo III, 1001 a 1250 g y grupo IV 1251 a 1500 g. Se analizó peso, edad gestacional, sexo, indicación inicial de ventilación mecánica, persistencia del conducto arterioso, displasia broncopulmonar, hemorragia intraventricular y mortalidad. Durante el período de estudio el 57.1 por ciento de pacientes con peso ó a 1,500 g, ameritaron ventilación mecánica (120/210). En el 70 por ciento de los casos la ventilación mecánica (VM) fue síndrome de dificultad respiratoria. La incidencia de volutrauma fue del 37.5 por ciento y de displasia broncopulmonar de 43.3 por ciento. El 25 por ciento (30/120) presentaron conducto arterioso sintomático. La incidencia de hemorragia intraventricular (HIV) fue del 53.3 por ciento. La mortalidad general para los pacientes con peso ó a 1,500 g fue del 24.3 por ciento y los que ameritaron VM fue del 42.5 por ciento. Estos resultados muestran una disminución en la mortalidad con respecto a años anteriores, con aumento en la morbilidad, principalmente displasia broncopulmonar y hemorragia subependimaria-intraventricular